Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study
Authors
Keywords
-
Journal
Gastroenterology Report
Volume 11, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2023-02-03
DOI
10.1093/gastro/goac088
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pancreatic Cancer
- (2021) Wungki Park et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)
- (2021) Se-Il Go et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
- (2020) Toshihiko Matsumoto et al. PANCREAS
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
- (2019) Andrea Wang-Gillam et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy
- (2018) Toru Aoyama et al. Journal of Cancer Research and Therapeutics
- Challenges in diagnosis of pancreatic cancer
- (2018) Lulu Zhang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
- (2018) Moon Jae Chung et al. World Journal of Gastrointestinal Oncology
- Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
- (2016) Hiroshi Imaoka et al. EUROPEAN JOURNAL OF CANCER
- Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
- (2014) Takuji Okusaka et al. CANCER SCIENCE
- FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
- (2012) Cindy Neuzillet WORLD JOURNAL OF GASTROENTEROLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now